The recommended 10 mg/kg Q2W ramucirumab dose combined with erlotinib (150 mg/day) is an efficacious and safe 1st line treatment for EGFR-mutated, metastatic NSCLC. Here, EGFR is linked to non-small cell lung carcinoma.